Choi criteria are superior to Response Evaluation Criteria in Solid Tumours (RECIST) for evaluating GI stromal tumours in imatinib-treated patients

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1588, 2007-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib: Phenotype change in GI stromal tumours: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1078, 2005-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Imatinib Mesylate: In the Treatment of Gastrointestinal Stromal Tumours

By Croom K.F.   Perry C.M.  

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 513-522

Adis International

Access to resources Recommend Favorite

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?

By Nilsson Bengt   Nilsson Ola   Ahlman Håkan  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 457-468

Informa Healthcare

Access to resources Recommend Favorite

Imatinib mesilate: new perspectives in the treatment of solid tumours

By Smirne Carlo   Carbone Anna   Pirisi Mario   Bellone Graziella  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 10, 2006-10 ,pp. : 1359-1370

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

By Huse Daniel M.  

Clinical Drug Investigation, Vol. 27, Iss. 2, 2007-01 ,pp. : 85-93

Adis International

Access to resources Recommend Favorite